Role of RNF213 p.4810K variant in the development of intracranial arterial disease in patients treated with nilotinib

Nilotinib, a tyrosine kinase inhibitor, used for the treatment of chronic myeloid leukemia (CML), is known to produce atherosclerotic complications such as coronary artery disease, peripheral artery disease [1] and intracranial arterial stenosis/occlusion (ICASO) [2,3]. Middle cerebral artery (MCA) is the most common site involved in ICASO in CML patients treated with nilotinib [2]. It has been remained unknown what factors influence the development of ICASO in patients treated with nilotinib. Because reported patients with ICASO were rare, there is a possibility that some specific factors such as genetic mutations are associated with ICASO under treatment with nilotinib.

Source: Journal of the Neurological Sciences - November 8, 2019 Category: Neurology Authors: Masahiro Uemura, Masato Kanazawa, Takuma Yamagishi, Takahiro Nagai, Mami Takahashi, Shingo Koide, Masayoshi Tada, Junsuke Shimbo, Aiko Isami, Kunihiko Makino, Masayoshi Masuko, Kouji Nikkuni, Kouichirou Okamoto, Shuichi Igarashi, Kenichi Morita, Osamu Ono Tags: Letter to the Editor Source Type: research